Results 261 to 270 of about 206,964 (305)

Angiotensin-converting enzyme 2 activation attenuates inflammation and oxidative stress in brain death donor followed by rat lung transplantation. [PDF]

Sci Rep
Oliveira-Melo P, Nepomuceno NA, Ruiz LM, Correia AT, Vilela VS, de Oliveira Braga KA, Manzuti GM, Feitosa DDM, Kennedy-Feitosa E, Wang A, Cypel M, Fernandes PMP.   +11 more
europepmc   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Angiotensin-converting enzyme 2 alleviates liver fibrosis through the renin-angiotensin system. [PDF]

World J Gastroenterol
Zhao BW, Chen YJ, Zhang RP, Chen YM, Huang BW.   +4 more
europepmc   +1 more source

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in ...
Viveca Ritsinger, Magnus Sundbom, Jonatan Dereke, Åsa Ericsson, Thomas Cars, Maria K. Svensson, Anna Norhammar   +6 more
wiley   +1 more source

Angiotensin-converting enzyme 2 and AMPK/mTOR pathway in the treatment of liver fibrosis: Should we consider further implications? [PDF]

World J Gastroenterol
Barone M.
europepmc   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Synthesis, molecular docking, and <i>in vitro</i> activity of a novel angiotensin-converting enzyme 2 inhibitor, LMS1007: a potential molecule in Covid-19 and cancer treatments. [PDF]

RSC Adv
Saadah L, Abu Deiab G, Al-Balas Q, Basheti I.   +3 more
europepmc   +1 more source

Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19. [PDF]

World J Gastroenterol
Jacobs AK, Morley SD, Samuel K, Morgan K, Boswell L, Kendall TJ, Dorward DA, Fallowfield JA, Hayes PC, Plevris JN.   +9 more
europepmc   +1 more source